Barclays raises target for Natera stock to USD 475

Published on 10/08/2026 at 16:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 37.70 percent to USD 752.75 million in 2026's second quarter. Natera stock stood at EUR 345.30 on October 8, 2026 versus EUR 353.30.

Key points in brief

Barclays raised its Natera price target to USD 475 from USD 340 on October 7, 2026.
Natera revenue rose 37.70 percent year over year to USD 752.75 million in the second quarter of 2026.
Natera stock was EUR 345.30 at Lang & Schwarz on October 8, 2026, down 2.26 percent versus the prior close.
The stock's 52-week range was USD 167.99 to USD 437.41, with market capitalization at USD 55.7 billion.

NTRA, US6323071042, Illustration mit AI erstellt.

Barclays raised its price target for Natera stock to USD 475 from USD 340 in a note dated October 7, 2026, while maintaining a Buy rating, according to Markets Insider. At Lang & Schwarz, Natera stock was trading at EUR 345.30 on October 8, 2026 at 4:35 p.m. CEST, down 2.26 percent versus the prior close of EUR 353.30.

Three milestones shape the story

On September 22, 2026, Natera said Signatera received authorization in Japan as a companion diagnostic for muscle-invasive bladder cancer, supporting a planned commercial launch in the first half of 2027, as reported by finanzen.ch.

On October 1, 2026, Guggenheim lifted its Natera target to USD 475 from USD 360 and kept a Buy rating, according to Markets Insider. Barclays followed on October 7, 2026, raising its target to the same USD 475 level from USD 340 while retaining Buy.

What supports the higher targets

Natera reported USD 752.75 million of revenue in the second quarter of 2026, up 37.70 percent from the year-ago quarter, according to MarketBeat. The company still reported a loss of USD 0.47 per share, although that was better than the USD 0.49 consensus loss and improved from a USD 0.74 loss in the year-ago quarter.

The figures explain the split in the investment case. Revenue growth and expanding Signatera applications support higher sales expectations, while the continuing loss keeps valuation sensitivity high after the share price approached its yearly peak.

Stock remains below its yearly high

Natera's 52-week range was USD 167.99 to USD 437.41 on October 8, 2026, leaving the Lang & Schwarz euro quote separate from the Nasdaq range because the currencies differ. Finance data put Natera's market capitalization at USD 55.7 billion on October 8, 2026.

Natera is listed on the NASDAQ under ticker NTRA and operates in healthcare, specifically medical diagnostics and research. Its portfolio spans reproductive health, oncology and organ-health testing, including Panorama, Signatera and Prospera.